Ketoprofen · DIN 00790427 · 50 mg · capsule
General benefitDormant since July 31, 2019 · checked November 18, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Ketoprofen · DIN 00790427
Manufacturer: A A Pharma Inc.; listing date 1996-10-01
Health Canada: Dormant since 2019-07-31 · brand KETOPROFEN · ATC M01AE03 KETOPROFEN · form Capsule · route Oral · ingredients KETOPROFEN 50 MG · company Aa pharma inc · schedule Prescription
Ketoprofen: Formulary list price $0.34 per unit (the source does not state the unit; exact figure $0.3440). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00790427)
Source record
DIN 00790427: Ketoprofen
Raw flags: sec3=Y
Item: 280804027; group id 384; item number 0919; lccId None; manufacturer id AAP
Source form: Cap; strength: 50mg
Recorded listing: General benefit
Source prices (unrounded): $0.3440; ministry $0.3440
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00790427
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10136
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Orudis · DIN 01926403 · not recorded
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Dormant since July 31, 2019 — choose a marketed DIN from the same-category list.